




ATN
Softtech®

07 January 2026

NeviTrack

AI-powered SiMD

The Longitudinal Intelligence Layer for Digital Dermatology



Turab Selçuk, Founding Partner

www.atnsofttech.com

Problem Statement


Pigmented skin lesions (nevi) are common and mostly benign, but in some patients they can transform into melanoma—a life-threatening skin cancer if not detected early.

Early melanoma signals lie in subtle lesion changes, but in existing systems, advanced analysis is delivered as optional software—driving up device prices and limiting objective longitudinal follow-up.


Solution

NeviTrack comprises a medical imaging hardware component and an SIMD-class software module that performs detection, longitudinal analysis, and classification of pigmented skin lesions.

Key benefits include:



AI-Powered Nevus Classification Software



Cost-effective pricing

Clinical Workflow Meets Longitudinal AI

Training data sourced from **multiple clinical** centers

All lesions are annotated and validated by board-certified **dermatologists**

After market launch, dermatologist-reviewed misdetections from new images are systematically incorporated into model **retraining** to continuously **improve AI** performance.



800/images


used for **nevus detection training** and tested on 200 images

25000/images

used for **lesion classification** training and tested on 5000 images

AI-assisted longitudinal tracking **Nevitrack** enables faster detection of new or changing lesions, improving clinical efficiency and reducing downstream treatment costs through earlier intervention.

Milestones



Early Clinical Validation

Ongoing comparative evaluation vs. FotoFinder with dermatologists reporting **stronger predictive follow-up insights**

Clinical data collection in progress.

First actionable clinical results expected **by April 1, 2026.**

Market Potential


The global dermatology imaging market represents a multi-billion-euro opportunity driven by rising melanoma incidence, increased demand for non-invasive diagnostics, and rapid adoption of AI-enabled clinical tools.



The dermatology imaging devices market is forecast to grow from approximately \$2.42 B in 2023 to


\$ 5,6 /billion

by 2030 at a ~13% CAGR



Source: Grand View Research – Dermatology Imaging Devices Market (2024–2030)

Go-to-Market



NeviTrack targets a **€45–50M** SOM (with the assumption of %2.5–3 SAM) over five years, based on ~1,000 early-adopter clinics with an average system price of **€46,000** and ~5% penetration.

NeviTrack will initially pursue a direct-to-clinic sales strategy to drive early adoption and clinical validation, with distributor partnerships planned for scalable market expansion.

NeviTrack will launch in Türkiye as its initial market, leveraging local clinical access and regulatory familiarity to accelerate validation before international expansion.

Typical sales cycle length (estimated): 3–6 months
(Includes initial contact, clinical demo, pilot use by dermatologists, and procurement decision by private clinics or hospitals.)

Competitive Landscape

Our competitors include:



FotoFinder Systems GmbH

High prices, paid software add-ons

Canfield Scientific, Inc.

High upfront cost, proprietary hardware

SkinVision B.V.

Designed mainly for patient self-screening rather than structured, clinician-led longitudinal monitoring

Funding Ask

We are seeking

€ 250K

to convert the prototype into a
commercial medical device.

Expected runway

€ 90K ——— **€ 160K**

Product development

Certification

Regulatory Strategy

- EU MDR Class IIa pathway
- IEC 62304 software lifecycle compliance
- Explainable and auditable AI

While premium competitors are priced at €54 K+ per system, NeviTrack enters the market at **€46K** with higher longitudinal clinical value and lower total cost of ownership.


A **10%** equity stake in the company is offered in exchange for the investment.

The primary investment structure targeted is **equity-based** investment.

Investors will receive standard information and reporting rights,
pro-rata participation in future rounds,
and minority protection provisions.

Traction

Early adopter clinic:
Kahramanmaraş
Sütçü İmam
University –Türkiye
Department of
Dermatology



5 units

in its first year of commercialization

50 units

in its fifth year of commercialization

€ 2,3 M

cumulative revenue at a €46K unit price.

Exit Strategy



By delivering structured, clinical-grade longitudinal intelligence at a lower cost—without paid software add-ons or proprietary hardware lock-in—NeviTrack is positioned for scalable adoption across dermatology clinics and a targeted exit within **5** years

Valuation

Based on comparable exits and revenue multiples in digital dermatology and medical imaging, NeviTrack targets a potential 5–10× return on early-stage investment

Next Steps

Upon successful field and commercial validation, the company plans to pursue a next funding round or explore acquisition opportunities with strategic players in the defense and healthcare technology sectors.

Team Overview

NECIP YILMAZ, CEO
10+ years in the defense
industry

TURAB SELÇUK, ASSOC.PROF.
Electrical & Electronics Engineer

ABDURRAHMAN YILMAZ, MD
Project Manager

BURÇIN KÖSE GEDİK, PHD
Business Development Manager



“We welcome
your questions
and feedback.”



Please reach out at

+90 5445165083



burcin.gedik@atnsofttech.com